MedTrace Logo

Investigating the Clinical Impact of a Novel Adipose Allograft Matrix on Knee Fat Pad Impingement Treatment

NCT05880888 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2025-04-01

No results posted yet for this study

Summary

This study is to assess the effect of Renuva® on fat pad regeneration in patients with Fat pad Impingement

Conditions

  • Fat Pad Syndrome

Interventions

BIOLOGICAL

Renuva

Renuva® (MTF Biologics) is an injectable decellularized allograft adipose matrix (AAM) used to increase volume in adipose tissue.

Sponsors & Collaborators

  • Ohio State University

    lead OTHER

Principal Investigators

  • Michael Baria · Ohio State University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-22
Primary Completion
2024-01-09
Completion
2025-02-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05880888 on ClinicalTrials.gov